Page last updated: 2024-11-13
chondrosine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
chondrosine: obtained by degradation of chondroitin sulfates; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 71586761 |
| CHEBI ID | 190123 |
| MeSH ID | M0188394 |
Synonyms (13)
| Synonym |
|---|
| chondrosine |
| CHEBI:190123 |
| 499-14-9 |
| (2s,3s,4s,5r,6r)-6-[(2r,3r,4s,5r)-2-amino-4,5,6-trihydroxy-1-oxohexan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid |
| 660o7jhz39 , |
| d-galactose, 2-amino-2-deoxy-3-o-beta-d-glucopyranuronosyl- |
| unii-660o7jhz39 |
| 2-amino-2-deoxy-3-o-(beta-d-glucopyranosyluronic acid)-d-galactose |
| chondrosine [who-dd] |
| chondrosine [mi] |
| WNWNYJSOBYTXFA-IJYCYIJYSA-N |
| DTXSID30198141 |
| Q27263926 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The bioavailability of chondrosine was evaluated by its direct measurement as found in the blood plasma following removal of plasma proteins by perchloric acid." | ( HPLC determination of chondrosine in mouse blood plasma after intravenous or oral dose. Igarashi, N; Kusano, S; Ootani, A; Sakai, S; Takeguchi, A; Toida, T; Toyoda, H, 2007) | 0.96 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| O-acyl carbohydrate | A carbohydrate derivative in which the hydrogen atom of at least one alcoholic hydroxy group of a carbohydrate has been replaced by an acyl substituent. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 16.71
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.71) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||